The synthesis and in vitro antibacterial and 13-lactamase inhibitory activity of the 2-azetidinone-l-oxysulfonic acids having a substituent at C-4 position of the p-lactam ring are described. The influence of C-4 substituents on the antibacterial activity was examined for the compounds having a-ureidoacetyl or a-oxyiminoacetyl group as acyl side chain at C-3 position. The antibacterial activity is correlated with the C-4 substituents and acyl side chain. Especially, 4(R)-methyl substituted derivatives exhibited excellent activity against Gram-negative bacteria and 4-dimethyl substituted derivatives exhibited strong activity against resistant Gram-negative bacteria except for Pseudomonas aeruginosa. 39 and 40 showed strong inhibitory activity against cephalosporinase of Enterobacter cloacae H-27.
The minimum inhibitory concentrations (MICs) of the 3-acylamino-2-azetidinone-l-oxysulfonic acids (12, 14 N 40) against several Gram-positive and Gram-negative bacteria are shown in Tables 1 N 3 .
Piperacillin (PIPC)11) and aztreonam12) were used as reference compounds. Table 1 shows the structure-activity relationships of 3-(a-ureido)acetamido-2-azetidinone-l-oxysulfonic acids in terms of substitution effect and configuration at C-3 and C-4 position. In this study, there was adopted the same acyl group as that used at 6-position of PIPC.
17, 21 and 22 with 4(R) configuration showed the most excellent activity against Gram-positive bacteria, however, despite of the increase of lipophilicity, 18, 19 and 20 showed less activity. Interestingly, 21 and 22 showed excellent activity against resistant strain Staphylococcus aureus F-137.
In general, the effect of substituent at C-4 contributed to the increase of antibacterial activity, as shown in this order CH3(R) > CH3(S) > H > di CH3 > > CH2CH3 > phenyl. Some of them showed neally the same antibacterial activity against Gram-negative bacteria as PIPC. Among them, 18 with di CH3 group at C-4 position and 21 with CH3(R) group at 6-position of piperazine ring showed excellent activity against ~ -lactamase-producing bacteria. On the other hand, 12 with the methoxy group at C-3 position lost considerably activity against our expectation, and, as expected, 14 with 3(R) configuration did not show any activity. Tables 2 and 3 show the structure-activity relationships of many monocyclic ~-lactam derivatives bearing the oxyiminoacetyl side chain which have been often used in conventional cephalosporins.
While the substituents at C-4 position being fixed CH3(R), the substitution effect (H and CH3) at C-4 position and the effect of lipophilicity of substituents in alkoxyimino group were investigated, and the result is shown in Table 2 . The effect of substituents at C-4 position showed that the compound with 4(R) configuration, one of cis form, showed better result against Gram-positive and Gram-negative bacteria, as shown in the following order 4-CH3(R)>4-CH3(S)>H.
As the lipophilicity of alkoxyimino side chain increased, compounds showed stronger activity against S. aureus (30, 31, 32). However, 26 showed excellent activity despite of low lipophilicity. On the other hand, they tended to show stronger antibacterial activity against Gram-negative bacteria in an inverse proportion to the increase of lipophilicity. As compared with a-ureidoacetyl derivatives, a-oxyiminoacetyl derivatives showed a little less effect against Gram-positive bacteria (shown in Table 1 ), however, possesed relatively broad spectrum of activity against Gram-negative bacteria and resistant strains. Among them, 28
with a-isopropyloxyimino side chain showed the best activity. Then, while a-propyloxyimino, carboxymethoxyimino and 1-carboxy-l-methylethoxyimino group being fixed as a moiety of acyl side chain, the effect of alkyl group at C-4 position was studied on synthesized compounds.
As the chain length of alkyl group at C-4 position extended, all compounds showed less activity against both Gram-positive bacteria and P. aeruginosa as shown in Table 1 
Determination of In Vitro Antibacterial Activity
All the in vitro antibacterial activities are given as the MIC in ,ug/ml. MICs were determined by the agar dilution method using heart infusion agar (Eiken) after incubation at 37°C for 20 hours and an inoculum size of about 104 cfu/ml.
Determination of In Vitro (5-Lactamase Inhibitory Activity (I50 Values) I50 values were determined by the method of MAK et al14). i9-Lactamases were used penicillinase (from E. coli TK-3) and cephalosporinase (from E. cloacae H-27). Various concentration of inhibitors were mixed with the same volume (about 20-100 p1) of the /9-lactamase-liquor. And the mixture were pre-incubated for 5 minutes at 30°C. Further, the mixture was added to 3 ml of 100 ,um benzylpenicillin or cephaloridin as the substrate. Preparation of Hydroxamate (2d) To a solution of (L)-N-Boc-/3-hydroxyvaline (Id) (20 g, 85.7 mmol) in CH2Cl2 (100 ml) was added N-methyl morpholine (9.71 ml, 88.3 mmol) under ice-cooling. ClCO2Et (8.6 ml, 90 mmol) in CH2Cl2 (20 ml) was added dropwise to the resulting solution at -30' -20°C over 15-20 minutes and the mixture was stirred at -20" -15°C for 1 hour. H2NOCH2Ph (10.66 g, 86.6 mmol) in CH2Cl2 (20 ml) was added dropwise to the resulting mixture at -30° -20°C over 15' 20 minutes and the mixture was stirred at -15-5'C for 1 hour. Water (100 ml) was dropped into the reaction mixture, and the mixture was extracted with CH2Cl2. Other hydroxamates (2e-.2i) were synthesized from the corresponding N-Boc amino acid in a similar manner as in 2d.
General Preparation of (3-Lactams (3) To a solution of hydroxamates (2) (20 mmol), Ph3P (40 mmol) and CCI, (40 mmol) in CH3CN
(140-160 ml) were added Et3N (45 mmol) at 3540°C, and the resulting mixture was stirred at 20-30'C for 1.5 hours.
The reaction mixture was evaporated and the residue was dissolved in EtOAc (200 ml). The solution was washed successively with H2O and brine, and then dried. The solvent was evaporated to give the residue, which was purified by column chromatography on silica gel (benzene -EtOAc, 10: 1) to afford 3. Results of 3 are summarized in Table 5 .
Preparation of 1-Hydroxy-2-azetidinone (4d) 3-Lactam (3d) (3.6 g, 11.25 mmol) was subjected to hydrogenolysis in MeOH (180 ml) for 30 minutes over 5 % Pd-C catalyst (400 mg) at room temp under 5 atmospheric pressure. The catalyst was filtered and washed with MeOH. The combined filtrate was evaporated to give the residue, which was triturated with IPE to afford 4d as white powders (2. Crude 1-hydroxy-2-azetidinone (4d) was used in subsequent steps without a further purification.
Other 1-hydroxy-2-azetidinones (4e-4i) were synthesized from the corresponding Q-lactams.
Preparation of 2-Azetidinone-1-oxysulfonate, Pyridinium Salt (5d)
To a solution of 1-hydroxy-2-azetidinone (4d) (2.2 g, 9.5 mmol) in DMF (4 -6 ml) was added sulfur trioxide-DMF complex (8.47 ml, 10.5 mmol) (1.24 mol solution in DMF) under ice-cooling and the mixture was stirred at the same temp for 30 minutes. Pyridine (0.93 ml, 11.5 mmol) was added to the resulting mixture, and the mixture was stirred for 5 minutes. Solvent was evaporated and the obtained residue was triturated with Et2O to afford 5d as colorless crystals (3.6 g, 97.3 %), which was used in subsequent steps without a further purification. Other 2-azetidinone-l-oxysulfonate, pyridinum salts (5e-5i) were synthesized from the corresponding 1-hydroxy-2-azetidinones.
General Preparation of 3-Amino-2-azetidinone-l-oxysulfonic Acids (6) To a solution of TFA (1.5 ml) in 1,2-dichloroethane (3.5 ml) was added 2-azetidinone-l-oxysulfonate, pyridinium salts (5) (8 mmol) under ice-cooling, and the mixture was stirred at the same temp for 2 hours. The precipitate was collected by filtration, washed with 1,2-dichloroethane, and dried over P2O, to afford 6. Results of 6 are summarized in Table 6 .
General Procedure for the Acylation of 3-Amino-2-azetidinone-l-oxysulfonic Acids Synthesis of 3-(a-Ureido)acetamido-2-azetidinone-l-oxysulfonic Acids (Method A) Preparation of 18, 19 and 20: To a mixture of 3-amino-2-azetidinone-l-oxysulfonic acids (6) (1 mmol) in CH2Cl2 (2" 3 ml) was added Et3N (2.2 mmol) at -40°C. D(-)-a-(4-Ethyl-2,3-dioxo-1-piperazinecarboxamido)phenylacetyl chloride17) (1.1 mmol) was added to the solution at the same temp. And the mixture was stirred for 30 minutes at -15--5°C, and further for an additional 1 hour at room temp. Table 6 . Yield, MP, IR and analytical data of 3-amino-2-azetidinone-l-oxysulfonic acids (6d-6i). a All the compound given the formular were analyzed for C, H, and N; analytical results obtained for these elements were within +0.4% of calculated values. Dil brine (5 ml) and THE (10 ml) were added to the reaction mixture, and the mixture was adjusted to pH 7.5 with Et3N. The organic layer was separated, washed with brine, then dried. The solvent was evaporated to give the residue, which was purified by column chromatography on silica gel (CHCl3-EtOH, 5: 1) to afford the Et3N salts of 18-20 in 60"70%yield.
(Method B) Preparation of 21 and 22: To a solution of 6c (1.5 mmol) in DMF (5 ml) was added Et3N (0.21 ml) under ice-cooling. D(-)-a-[(6R or 6S)-4-Ethyl-6-methyl-2,3-dioxo-l-piperazinecarboxamido]phenylacetic acid18) (1.35 mmol) and DCC (1.5 mmol) was added to the solution. And the mixture was stirred for 2 hours at room temp. The insolubles were filtered off and the filtrate was evaporated. The residue was purified by column chromatography on silica gel (CHCl3 -EtOH, 5: 1) to afford the Et3N salts of 21 and 22 in 54.2 and 50.2 % yield, respectively.
Synthesis of 3-(a-Oxyimino)acetamido-2-azetidinone-l-oxysulfonic Acids (Method C) Preparation of 2630, 32 and 33: To a solution of 6(1 mmol) in DMF (5 ml) was added Et3N (1 mmol) under ice-cooling. 2-(2-Triphenylmethylaminothiazol-4-yl)-(Z)-2-(O-substituted alkoxyimino)acetic acid (0.95 mmol), 1-hydroxybenzotriazole hydrate (1 mmol), molecular sieves 4A (1 g) and DCC (1 mmol) were added to the solution at the same temp and the mixture was stirred overnight at room temp. The insolubles were filtered off and the filtrate was dropped into IPE (300 ml). The solvent was removed by decantation and the obtained precipitate was purified by column chromatography on silica gel (CHCl3 -EtOH, 5: 1) to afford the Et3N salts of 3-[2-(2-triphenylmethylaminothiazol-4-yl)-(Z)-2-(O-substituted alkoxyimino)acetamido]-2-azetidinonel -oxysulfonic acids as an amorphous or oily substance in 60-80% yield. Thus obtained compounds were dissolved in THE (3 ml) and 50 % aq HCOOH (3 ml), and kept at 45 -50°C for 30 minutes. The solvent was evaporated to give the colorless oil, which was applied to a column of Dowex-50W (Na+ form) ion-exchange resin (10 ml) (eluant; H2O) to afford crude sodium salts. Sodium salt of each compound was purified by column chromatography on Amberlite XAD-2 (30 ml) (nonionic polymeric adsorbent) (eluant; H2O) to afford the sodium salts of 27, 28, 30, 32 and 33 as white powders in 40-50% yield.
The coloress oil obtained above was directly purified by column chromatography on Amberlite XAD-2 without the application of Dowex column to afford 26 and 29 as white powders in 50% yield, respectively.
( (Method E) Preparation of 37, 38 and 40: Triethylammonium 3-[2-(2-aminothiazol-4-yl)-(Z )-2-(1-tert-butoxycarbonyl-l-methylethoxyimino)acetamido or (1-tert-butoxycarbonyl-l-ethoxyimino)-acetamido]-2-azetidinone-l-oxysulfonate obtained in a similar manner as in Method C was dissolved in CH2Cl2 (15 ml). TFA (10 ml) was added to the solution under ice-cooling, and reacted for 2 hours. 20 ml of IPE was added to the reaction mixture. The formed precipitate was filtered, washed with IPE, and dried under reduced pressure over P2O5. The obtained substances were subjected to Dowex-50W and Amberlite XAD-2 column chromatography in a similar manner as in Method C to afford respective sodium salt in 40' 50 % yield. (3R,4R)-3-Amino-4-methyl-l-(p-nitrobenzyloxy)-2-azetidinone (8) To a solution of 7 (10 g, 27 mmol) in CH2Cl2 (100 ml) and N,N-dimethylaniline (6.86 ml, 54.2 mmol) was added portionwise PCl5 (7.33 g, 35.2 mmol) with stirring over 20 minutes at -50" -45°C.
